Session 2: Predictive Models in Portal Hypertension

Portal Hypertension IV: Proceedings of the 4th Baveno International Consensus Workshop

Volumn , Issue , 2007, Pages 47-100

  Garcia Tsao, Guadalupe ^a   D'Amico, Gennaro ^b   Abraldes, Juan G ^c   Schepis, Filippo ^d   Merli, Manuela ^e   Kim, W Ray ^f   Christensen, Erik ^g  

^a YALE UNIVERSITY   (United States)

^b VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Mayo Clinic   (United States)

^g BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Cirrhosis; Hepatic venous pressure gradient; Hepatocellular carcinoma; Model for end stage liver disease; Variceal haemorrhage

Indexed keywords

EID: 84986591586     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988831.ch4     Document Type: Chapter

References (96)

1. D'Amico G, Garcia-Tsao G, Cales P et al. Diagnosis of portal hypertension: how and when. In: de Franchis R (ed). Portal hypertension III. Proceedings of the third Baveno international consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. Blackwell Science, Oxford, 2001; 36-64.
2. Saunders JB, Walters JRF, Davies P, Paton A. A 20-year prospective study of cirrhosis. Brit Med J. 1981;282: 263-266.
3. Gines P, Quintero E, Arroyo V. Compensated cirrhosis: natural history and prognosis. Hepatology. 1987;7: 122-128.
4. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986; 31:468-475.
5. D'Amico G, Licata A, Pasta L, Rizzuto G, D'Amico M, Mocciaro F. Prognostic indicators in cirrhosis: the role of Child classification. Overview of 93 published studies and validation in a prospective cohort of patients. Dig Liver Dis. 2005;37:(29).
6. D'Amico G, Pasta L, Madonia S et al. The incidence of esophageal varices in cirrhosis. Gastroenterology. 2001;120: A2.
7. Pugh RN, Murray-Lyon IM, Dawson JL, Pietrini MC, Williams R. Transection of the esophagus for bleeding oesophageal varices. Br J Surg. 1973;60: 646-649.
8. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33: 464-470.
9. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(suppl.): S100-S107.
10. Boyer TD, Triger DR, Horisawa M, Redeker AG, Reynolds TB. Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology. 1977;72: 584-589.
11. Perello A, Escorsell A, Bru C et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology. 1999;30:1393-1397.
12. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39: 280-283.
13. Morali GA, Sniderman KW, Deitel KM et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol. 1992;16:249-250.
14. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5: 419-424.
15. Viallet A, Marleau D, Huet M et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology. 1975;69: 1297-1300.
16. Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D. Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut. 1986;27: 1204-1209.
17. Gluud C, Henriksen JH, Nielsen G and the Copenhagen Study Group for Liver Disease. Prognostic indicators in alcoholic cirrhotic men. Hepatology. 1988;8:222-227.
18. Stanley AJ, Robinson I, Forrest EH, Jones AL, Hayes PC. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. QJM. 1998;91: 19-25.
19. Le Moine O, Hadengue A, Moreau R et al. Relationship between portal pressure, esophageal varices, and variceal bleeding on the basis of the stage and cause of cirrhosis. Scand J Gastroenterol. 1997;32: 731-735.
20. Vorobioff J, Groszmann RJ, Picabea E et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996;111: 701-709.
21. Groszmann RJ, Bosch J, Grace N et al. Hemodynamic events in a prospective randomized trial of propranolol vs placebo in the prevention of the first variceal hemorrhage. Gastroenterology. 1990;99(5):1401-1407.
22. Groszmann RJ, Garcia-Tsao G, Makuch RW et al. Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factors. Hepatology. 2003;38(suppl. 1): 206A (abstract).
23. Merkel C, Bolognesi M, Sacerdoti D et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000;32:930-934.
24. Moller S, Bendtsen F, Christensen E, Henriksen JH. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J Hepatol. 1994;21: 940-946.
25. Turnes J, Garcia-Pagan JC, Abraldes JG et al. Pharmacological reduction of portal pressure and long term risk of first variceal bleeding in patients with cirrhosis. Hepatology. 2003;38: 62A.
26. Zimmerer J, Haubitz I, Mainos D, Hadass H, Tittor W. Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification. Z Gastroenterol. 1996;34: 421-427.
27. Merkel C, Bolognesi M, Bellon S et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology. 1992;102: 973-979.
28. Urbain D, Muls V, Makhoul E, Jeghers O, Thys O, Ham HR. Prognostic significance of hepatic venous pressure gradient in medically treated alcoholic cirrhosis:comparison to aminopyrine breath test. Am J Gastroenterol. 1993;88:856-859.
29. Tage-Jensen U, Henriksen JH, Christensen E, Widding A, Ring-Larsen H, Christensen NJ. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol. 1988;6(3):350-358.
30. Escorsell A, Bordas JM, Castaneda B et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology. 2000;31: 1061-1067.
31. Bureau C, Peron JM, Alric L et al. 'A La Carte' treatment of portal hypertension:adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology. 2002;36: 1361-1366.
32. Deltenre P, Rufat P, Hillaire S et al. Lack of prognostic usefulness of hepatic venous pressures and hemodynamic values in a select group of patients with severe alcoholic cirrhosis. Am J Gastroenterol. 2002;97: 1187-1190.
33. Dittrich S, de Mattos AA, Becker M, Goncaves DM, Cheinquer H. Role of hepatic hemodynamic study in the evaluation of patients with cirrhosis. Hepatogastroenterology. 2003;50: 2052-2056.
34. Lebrec D, De Fleury P, Rueff B, Nahum H, Benhamou JP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology. 1980;79: 1139-1144.
35. Merkel C, Zoli M, Siringo S et al. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) Index. Am J Gastroenterol. 2000;95:2915-2920.
36. Vinel JP, Cassigneul J, Levade M, Voigt JJ, Pascal JP. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. Hepatology. 1986;6: 116-117.
37. Ready JB, Robertson AD, Goff JS, Rector WG Jr. Assessment of the risk of bleeding from esophageal varices by continuous monitoring of portal pressure. Gastroenterology. 1991;100: 1403-1410.
38. Moitinho E, Escorsell A, Bandi JC et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology. 1999;117: 626-631.
39. Villanueva C, Ortiz J, Minana J et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during active variceal bleeding. Gastroenterology. 2001;121: 110-117.
40. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40: 793-801.
41. Patch D, Armonis A, Sabin C et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut. 1999;44: 264-269.
42. Villanueva C, Balanzo J, Novella MT et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 1996;334: 1624-1629.
43. Feu F, Garcia-Pagan JC, Bosch J et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995;346: 1056-1059.
44. Villanueva C, Minana J, Ortiz J et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med. 2001;345: 647-655.
45. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and longterm prognosis of cirrhosis. Hepatology. 2003;37: 902-908.
46. Villanueva C, Lopez-Balaguer JM, Aracil C et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40: 757-765.
47. Patch D, Goulis J, Gerunda G, Greenslade L, Merkel C, Burroughs AK. A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology. 2002;123: 1013-1019.
48. McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK. Clinical vs hemodynamic response to drugs in portal hypertension. J Hepatol. 1998;28: 1015-1019.
49. Villanueva C, Lopez-Balaguer JM, Aracil C, Balanzo J. Reply to letter to the editor. J Hepatol. 2005;42: 147-148.
50. Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure. Gastroenterology. 1996;111: 1018-1022.
51. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30: 1434-1440.
52. DeFranchis R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33: 846-852.
53. D'Amico G. Esophageal varices: from appearance to rupture: natural history and prognostic indicators. In: Grossmann R, Bosch J (eds). Portal hypertension in 21st century, Dordrecht, The Netherlands, Kluwer Academic Publishers, 2004; 147-154.
54. Spiegel BM, Targownik L, Dulai GS, Karsan HA, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective? Hepatology. 2003;37: 366-377.
55. Cales P, Desmorat H, Vinel JP et al. Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. Gut. 1990;31:1298-1302.
56. Merkel C, Marin R, Angeli P et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology. 2004;127: 476-484.
57. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension:an evidence-based approach. Sem Liv Dis. 1999;19: 475-505.
58. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology. 2001;33:802-807.
59. Ng FH, Wong SY, Loo CK, Lam KM, Lai CW, Cheng CS. Prediction of oesophagogastric varices in patients with liver cirrhosis. J Gastroenterol Hepatol. 1999;14:785-790.
60. Cottone M, D'Amico G, Maringhini A et al. Predictive value of ultrasonography in the screening of non-ascitic cirrhotic patients with large varices. J Ultrasound Med. 1986;5: 189-192.
61. Chalasani N, Imperiale TF, Ismail A et al. Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol. 1999;94: 3285-3291.
62. Pilette C, Oberti F, Aube C et al. Non-invasive diagnosis of esophageal varices in chronic liver disease. J Hepatol. 1999;31: 867-873.
63. Schepis F, Camma C, Niceforo D et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology. 2001;33: 333-338.
64. Zaman A, Becker T, Lapidus J, Benner K. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med. 2001;161: 2564-2570.
65. Madhotra R, Mulcahy HE, Willner I, Reuben A. Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol. 2002;34: 81-85.
66. Giannini E, Botta F, Borro P et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut. 2003;52: 1200-1205.
67. Thomopoulos KC, Labropoulou-Karatza C, Mimidis KP, Katsakoulis EC, Iconomou G, Nikolopoulou VN. Non-invasive predictors of the presence of large oesophageal varices in patients with cirrhosis. Dig Liver Dis. 2003;35:473-478.
68. Dragoni F, Gentile G, Cartoni C et al. The role of real-time ultrasonography in predicting esophageal varices in hemophiliacs co-infected with hepatitis C and human immunodeficiency virus. Haematologica. 2005;90: 207-213.
69. Vanbiervliet G, Barjoan-Marine E, Anty R et al. Serum fibrosis markers can detect large oesophageal varices with a high accuracy. Eur J Gastroenterol Hepatol. 2005;17: 333-338.
70. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology. 2004;39: 204-210.
71. Bressler B, Pinto R, El Ashry D, Heathcote EJ. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? Gut. 2005;54: 407-410.
72. D'Amico G, Morabito A. Noninvasive markers of esophageal varices: another round, not the last. Hepatology. 2004;39: 30-34.
73. Vanbiervliet G, Rakotoarisoa C, Filippi J et al. Diagnostic accuracy of a rapid urine-screening test (Multistix8SG) in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2002;14: 1257-1260.
74. Burroughs AK, Groszmann RJ, Bosch J et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C. Is hepatic venous pressure gradient (HVPG) a better endpoint? Gut. 2002;50: 425-427.
75. Sanjal AJ, Fontana R, Everhart J, Di Bisceglie A, Wtight E. The presence and spectrum of varices in the absence of cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38: 218A.
76. Merli M, Nicolini G, Angeloni S et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38: 266-272.
77. Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology. 1989;96: 1552-1559.
78. Gentilini P, Laffi G, La Villa G et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol. 1997;92: 66-72.
79. Zoli M, Merkel C, Magalotti D et al. Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am J Gastroenterol. 2000;95:503-508.
80. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319: 983-989.
81. Sarin SK, Lamba G, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. New Eng J Med. 1999;340: 988-993.
82. Nidegger D, Ragot S, Berthelemy P et al. Cirrhosis and bleeding: the need for very early management. J Hepatol. 2003;39: 509-514.
83. El Atti EA, Nevens F, Bogaerts K, Verbeke G, Fevery J. Variceal pressure is a strong predictor of variceal haemorrhage in patients with cirrhosis as well as in patients with non-cirrhotic portal hypertension. Gut. 1999;45: 618-621.
84. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? J Hepatol. 2004;41:344-350.
85. Zoli M, Cordiani MR, Marchesini G et al. Prognostic indicators in compensated cirrhosis. Am J Gastroenterol. 1991;86: 1508-1513.
86. Zoli M, Iervese T, Merkel C et al. Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. J Hepatol. 1993;17: 56-61.
87. Realdi G, Fattovich G, Hadziyannis S et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1994;21: 656-666.
88. Fattovich G, Giustina G, Christensen E et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (EUROHEP). Gut. 2000;46:420-426.
89. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112: 463-472.
90. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis:a cohort study of 297 patients. Am J Gastroenterol. 2002;97: 2886-2895.
91. Cardenas A, Gines P, Uriz J et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology. 2001;34: 671-676.
92. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1: 1-85.
93. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, TerBorg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31: 864-871.
94. D'Amico G, de Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38: 599-612.
95. Heuman DM, Abou-Assi SG, Habib A et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40: 802-810.
96. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11: 336-343.